Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$25.17 USD
-1.18 (-4.48%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $25.16 -0.01 (-0.04%) 6:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Akero Therapeutics, Inc. [AKRO]
Reports for Purchase
Showing records 81 - 100 ( 108 total )
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dial In to Part 1 of Our Three-Part NASH Call Series Tomorrow at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Revisit NASH in 2020: Join Our Three-Part Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -Join Our 1Q20 Doc Call Series in PWS, NASH, Omega-3s and Contraception
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NASH Weekly: 2020 Is Packed With Clinical Data Readouts in NASH
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NASH Weekly: GLP-1 Data in 2Q20 Is Likely to Be Underwhelming
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As we are three weeks away from JPM Healthcare conference.
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Yas'' Weekly Recap of Our Key Notes
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Expert Call Recap for 2019 in NASH and Liver Disease
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Should You Attend AASLD in Boston? Use Our Day-By-Day Calendar to Figure It Out
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from Our Doc Call with Dr. Arun Sanyal
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - September is the Key Month for NASH: Join Our Three Doc Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y